Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abcam plc stock logo
ABCZF
Abcam
C$22.25
C$22.25
C$5.00
C$23.80
N/AN/A2,659 shsN/A
ADOIF
Adocia
C$8.87
C$8.87
C$8.87
C$11.24
N/AN/A2,000 shsN/A
Abattis Bioceuticals Corp. stock logo
ATTBF
Abattis Bioceuticals
$0.00
$0.00
$0.00
N/AN/A11,650 shsN/A
TRSBF
3SBio
$0.80
$0.80
$0.80
$0.80
N/AN/A63,275 shsN/A
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abcam plc stock logo
ABCZF
Abcam
0.00%0.00%0.00%0.00%+44.48%
ADOIF
Adocia
0.00%0.00%0.00%0.00%0.00%
Abattis Bioceuticals Corp. stock logo
ATTBF
Abattis Bioceuticals
0.00%0.00%0.00%0.00%0.00%
TRSBF
3SBio
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Abcam plc stock logo
ABCZF
Abcam
N/AN/AN/AN/AN/AN/AN/AN/A
ADOIF
Adocia
N/AN/AN/AN/AN/AN/AN/AN/A
Abattis Bioceuticals Corp. stock logo
ATTBF
Abattis Bioceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
TRSBF
3SBio
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Abcam plc stock logo
ABCZF
Abcam
N/AN/AN/AN/A
ADOIF
Adocia
N/AN/AN/AN/A
Abattis Bioceuticals Corp. stock logo
ATTBF
Abattis Bioceuticals
N/AN/AN/AN/A
TRSBF
3SBio
N/AN/AN/AN/A

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Abcam plc stock logo
ABCZF
Abcam
N/AN/AN/AN/AN/AN/A
ADOIF
Adocia
N/AN/AN/AN/AN/AN/A
Abattis Bioceuticals Corp. stock logo
ATTBF
Abattis Bioceuticals
N/AN/AN/AN/AN/AN/A
TRSBF
3SBio
N/AN/AN/AN/AN/AN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Abcam plc stock logo
ABCZF
Abcam
N/AC$0.17130.73N/AN/AN/AN/AN/A
ADOIF
Adocia
N/AN/A0.00N/AN/AN/AN/AN/A
Abattis Bioceuticals Corp. stock logo
ATTBF
Abattis Bioceuticals
N/A-$0.16N/AN/AN/AN/AN/AN/AN/A
TRSBF
3SBio
N/AN/A0.00N/AN/AN/AN/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Abcam plc stock logo
ABCZF
Abcam
C$0.070.32%N/A42.48%N/A
ADOIF
Adocia
N/AN/AN/AN/AN/A
Abattis Bioceuticals Corp. stock logo
ATTBF
Abattis Bioceuticals
N/AN/AN/AN/AN/A
TRSBF
3SBio
N/AN/AN/AN/AN/A

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Abcam plc stock logo
ABCZF
Abcam
43.58%
ADOIF
Adocia
N/A
Abattis Bioceuticals Corp. stock logo
ATTBF
Abattis Bioceuticals
32.45%
TRSBF
3SBio
N/A

Insider Ownership

CompanyInsider Ownership
Abcam plc stock logo
ABCZF
Abcam
N/A
ADOIF
Adocia
N/A
Abattis Bioceuticals Corp. stock logo
ATTBF
Abattis Bioceuticals
N/A
TRSBF
3SBio
N/A

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Abcam plc stock logo
ABCZF
Abcam
1,760N/AN/ANot Optionable
ADOIF
Adocia
97N/AN/ANot Optionable
Abattis Bioceuticals Corp. stock logo
ATTBF
Abattis Bioceuticals
N/AN/AN/ANot Optionable
TRSBF
3SBio
5,411N/AN/ANot Optionable

ATTBF, TRSBF, ABCZF, and ADOIF Headlines

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Abcam logo

Abcam

OTCMKTS:ABCZF
Abcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. The company's principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex immunoassays; proteins and peptides that include cytokines; edited cell lines and lysates; and various other products, including cellular activity kits, biochemicals, and cell signaling pathway tools. It serves scientists and researchers in academic institutions and research institutes, as well as in pharmaceutical, biotechnology, and diagnostics companies. The company has operations in the Americas, Europe, the Middle East, Africa, China, Japan, and rest of the Asia Pacific. It sells its products online. The company was incorporated in 1998 and is headquartered in Cambridge, the United Kingdom. As of December 6, 2023, Abcam plc operates as a subsidiary of Danaher Corporation.

Adocia

OTCMKTS:ADOIF
Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary BioChaperone technological platform provides molecular delivery of therapeutic proteins. The company's clinical product pipeline includes insulin formulations, such as BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid insulin lispro; BioChaperone Combo, a combination of acting insulin glargine and rapid-acting insulin lispro; BioChaperone LisPram, a combination of prandial insulin with pramlintide; and BioChaperone Glucagon, an aqueous formulation of human glucagon for the treatment of hypoglycemia, as well as M1Pram, a metabolite of insulin glargine and pramlintide. Its preclinical pipeline includes products for the treatment of diabetes and obesity comprising AdoShell Islets, an implant containing islets of Langerhans; AdOral Sema, an oral delivery of semaglutide; and BioChaperone GluExe, a combination of glucagon and exenatide. The company has a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. to develop and commercialize BioChaperone Lispro and BioChaperone Combo in China and other Asian and Middle Eastern territories. Adocia SA was incorporated in 2005 and is headquartered in Lyon, France.
Abattis Bioceuticals logo

Abattis Bioceuticals

OTCMKTS:ATTBF
Abattis Bioceuticals Corp. operates as a life sciences and biotechnology company in Canada. The company develops and licenses natural health products, medicines, extractions, and ingredients for the biological, nutraceutical, bioceutical, and cosmetic markets. It also provides Comfort, a cannabinoid enhanced nutraceutical for pain and inflammation; and Health-Canada licensed services for the cannabis industry. The company was formerly known as Abattis Biologix Corporation and changed its name to Abattis Bioceuticals Corporation in September 2012. Abattis Bioceuticals Corp. was incorporated in 1997 and is headquartered in Vancouver, Canada.

3SBio

OTCMKTS:TRSBF
3SBio Inc., an investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; Cipterbin, an anti-HER2 monoclonal antibody for the treatment of HER2-positive metastatic breast cancer in combination with chemotherapy; Interferon, a human interferon a2a for injection; and Inleusin, for the treatment of renal cell carcinoma, melanoma, thoracic fluid build-up caused by cancer and tuberculosis. It also offers YISAIPU, the receptor-antibody fusion tumor necrosis factor inhibitor; Mendi-minoxidil tincture, an OTC external medicine for treating hair loss; EPIAO and SEPO, an erythropoietin injection; SPARIN, an injectable low-molecular-weight heparin calcium; and Xenopax, a recombinant humanized anti-cd25 monoclonal antibody injection for prevention of acute rejection after renal transplantation. In addition, the company provides TPO-105 Pediatric ITP; SSS12 Cinacalcet hydrochloride; SSS13 Sevelamer carbonate; 301S TNFR-Fc protein; AP506 Apremilast; SSS32 Tofacitinib; and MN709 Minoxidil Foam. Further, the company provides trading, project management and consultation, technology, sports, financial, investment advisory, and agricultural services. It has collaboration agreements with companies, such as Toray Industries Inc, and Toray. The company was founded in 1993 and is headquartered in Shenyang, the People's Republic of China.